Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".

Int J Mol Sci · 2023 · PMC10743607 · PMID 38139149

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

This disadvantage may not be significant or even beneficial (if it causes a frameshift) in the case of PE-mediated gene knockouts.

also in 1,197 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.